Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer.
Muller M, Best MG, van der Noort V, Hiltermann TJN, Niemeijer AN, Post E, Sol N, In 't Veld SGJG, Nogarede T, Visser L, Schouten RD, van den Broek D, Hummelink K, Monkhorst K, de Langen AJ, Schuuring E, Smit EF, Groen HJM, Wurdinger T, van den Heuvel MM. Muller M, et al. Among authors: monkhorst k. Tumour Biol. 2024;46(s1):S327-S340. doi: 10.3233/TUB-220037. Tumour Biol. 2024. PMID: 37270827 Free article.
Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
Schipper LJ, Samsom KG, Snaebjornsson P, Battaglia T, Bosch LJW, Lalezari F, Priestley P, Shale C, van den Broek AJ, Jacobs N, Roepman P, van der Hoeven JJM, Steeghs N, Vollebergh MA, Marchetti S, Cuppen E, Meijer GA, Voest EE, Monkhorst K. Schipper LJ, et al. Among authors: monkhorst k. ESMO Open. 2022 Dec;7(6):100611. doi: 10.1016/j.esmoop.2022.100611. Epub 2022 Dec 1. ESMO Open. 2022. PMID: 36463731 Free PMC article.
SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response.
Ibáñez-Molero S, van Vliet A, Pozniak J, Hummelink K, Terry AM, Monkhorst K, Sanders J, Hofland I, Landeloos E, Van Herck Y, Bechter O, Kuilman T, Zhong W, Marine JC, Wessels L, Peeper DS. Ibáñez-Molero S, et al. Among authors: monkhorst k. Oncoimmunology. 2022 Nov 29;11(1):2139074. doi: 10.1080/2162402X.2022.2139074. eCollection 2022. Oncoimmunology. 2022. PMID: 36465485 Free PMC article.
A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non-small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics.
Hummelink K, Tissier R, Bosch LJW, Krijgsman O, van den Heuvel MM, Theelen WSME, Damotte D, Goldwasser F, Leroy K, Smit EF, Meijer GA, Thommen DS, Monkhorst K. Hummelink K, et al. Among authors: monkhorst k. Clin Cancer Res. 2024 Feb 16;30(4):814-823. doi: 10.1158/1078-0432.CCR-23-1061. Clin Cancer Res. 2024. PMID: 38088895 Free PMC article.
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer.
Murray JC, Sivapalan L, Hummelink K, Balan A, White JR, Niknafs N, Rhymee L, Pereira G, Rao N, Weksler B, Bahary N, Phallen J, Leal A, Bartlett DL, Marrone KA, Naidoo J, Goel A, Levy B, Rosner S, Hann CL, Scott SC, Feliciano J, Lam VK, Ettinger DS, Li QK, Illei PB, Monkhorst K, Scharpf RB, Brahmer JR, Velculescu VE, Zaidi AH, Forde PM, Anagnostou V. Murray JC, et al. Among authors: monkhorst k. Clin Cancer Res. 2024 Jan 17;30(2):389-403. doi: 10.1158/1078-0432.CCR-23-1469. Clin Cancer Res. 2024. PMID: 37939140 Free PMC article.
Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice.
Samsom KG, Bosch LJW, Schipper LJ, Schout D, Roepman P, Boelens MC, Lalezari F, Klompenhouwer EG, de Langen AJ, Buffart TE, van Linder BMH, van Deventer K, van den Burg K, Unmehopa U, Rosenberg EH, Koster R, Hogervorst FBL, van den Berg JG, Riethorst I, Schoenmaker L, van Beek D, de Bruijn E, van der Hoeven JJM, van Snellenberg H, van der Kolk LE, Cuppen E, Voest EE, Meijer GA, Monkhorst K. Samsom KG, et al. Among authors: monkhorst k. Nat Protoc. 2024 Mar;19(3):700-726. doi: 10.1038/s41596-023-00933-5. Epub 2023 Dec 13. Nat Protoc. 2024. PMID: 38092944 Review.
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.
Douma LH, Lalezari F, van der Noort V, de Vries JF, Monkhorst K, Smesseim I, Baas P, Schilder B, Vermeulen M, Burgers JA, de Gooijer CJ. Douma LH, et al. Among authors: monkhorst k. Lancet Oncol. 2023 Nov;24(11):1219-1228. doi: 10.1016/S1470-2045(23)00446-1. Epub 2023 Oct 13. Lancet Oncol. 2023. PMID: 37844598 Clinical Trial.
Activation of the beta globin locus by transcription factors and chromatin modifiers.
McMorrow T, van den Wijngaard A, Wollenschlaeger A, van de Corput M, Monkhorst K, Trimborn T, Fraser P, van Lohuizen M, Jenuwein T, Djabali M, Philipsen S, Grosveld F, Milot E. McMorrow T, et al. Among authors: monkhorst k. EMBO J. 2000 Sep 15;19(18):4986-96. doi: 10.1093/emboj/19.18.4986. EMBO J. 2000. PMID: 10990462 Free PMC article.
104 results